Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
For up-to-date information on clinical trials in the UK, the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) is the recommended patient-facing resource
Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days
, L- 30-40 2-3
Zhong G, Qin S, Townsend D, Schulte BA, Tew KD, Wang GY
US$ 27.93
US$ 25.45
US$ 27.62
US$ 22.03
US$ 20.79
